US2020031939A1PendingUtilityA1

Antibodies Against Human NKG2D and Uses Thereof

Assignee: NOVO NORDISK ASPriority: Dec 14, 2007Filed: Oct 17, 2019Published: Jan 30, 2020

Est. expiryDec 14, 2027(~1.4 yrs left)· nominal 20-yr term from priority

Inventors:Birgitte Urso Peter Andreas Nicolai Reumert Wagtmann Inger Lund Pedersen Anders Svensson

A61P 37/00A61P 37/02A61P 37/06A61P 29/00A61P 25/00A61P 3/00A61P 1/00A61P 21/00A61P 19/02A61P 1/04A61P 17/00A61P 17/06C07K 2317/76C07K 2317/55C07K 16/2851C07K 2317/34C07K 2317/565C07K 2317/92C07K 2317/24C07K 2317/56C07K 2317/74C07K 2317/21C07K 2299/00

PatentIndex Score

Cited by

References

Claims

Abstract

As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Claims

exact text as granted — not AI-modified

1 . A method of treating an inflammatory disease or disorder with an isolated antibody or an antigen-binding fragment thereof which binds human NKG2D (hNKG2D) and comprises
 (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO:48;   (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO:49;   (c) a heavy-chain variable region CDR3 comprising the sequence of SEQ ID NO:50;   (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO:51;   (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO:52; and   (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO:53.   
     
     
         2 . A method of treating an autoimmune disease or disorder with an isolated antibody or an antigen-binding fragment thereof which binds human NKG2D (hNKG2D) and comprises
 (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO:48;   (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO:49;   (c) a heavy-chain variable region CDR3 comprising the sequence of SEQ ID NO:50;   (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO:51;   (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO:52; and   (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO:53.   
     
     
         3 . A method of producing an isolated antibody or an antigen-binding fragment thereof which binds human NKG2D (hNKG2D) and comprises
 (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO:48;   (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO:49;   (c) a heavy-chain variable region CDR3 comprising the sequence of SEQ ID NO:50;   (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO:51;   (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO:52; and   (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO:53, comprising culturing a host cell comprising a nucleic acid encoding the antibody or antigen binding fragment under suitable conditions and recovering said antibody or antigen binding fragment thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.